Cytokines

Sequential interleukin-17/interleukin-23 inhibition in treatment-refractory psoriatic arthritis
David Simon, Filippo Fagni, Georg Schett

Annals of the Rheumatic Diseases May 2022, annrheumdis-2022-222415; DOI: 10.1136/annrheumdis-2022-222415
Correspondence on ‘No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related ‘physician-reported spondylitis’?’ by Braun and Landewé
Dafna D Gladman, Philip J Mease, Paul Bird, Enrique R Soriano, Soumya D Chakravarty, May Shawi, Frederic Lavie, Cinty Gong, Evan Leibowitz, Denis Poddubnyy, Lai-Shan Tam, Philip S Helliwell, Arthur Kavanaugh, Atul A Deodhar, Mikkel Østergaard, Xenofon Baraliakos

Annals of the Rheumatic Diseases Apr 2022, annrheumdis-2022-222161; DOI: 10.1136/annrheumdis-2022-222161
Anti-RNP antibodies are associated with the interferon gene signature but not decreased complement levels in SLE
Erika L Hubbard, David S Pisetsky, Peter E Lipsky

Annals of the Rheumatic Diseases May 2022, 81 (5) 632-643; DOI: 10.1136/annrheumdis-2021-221662
No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related ‘physician-reported spondylitis’?
Juergen Braun, Robert BM Landewé

Annals of the Rheumatic Diseases Apr 2022, 81 (4) 466-468; DOI: 10.1136/annrheumdis-2021-221422
Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study
Evgeniy Nasonov, Saeed Fatenejad, Eugen Feist, Mariana Ivanova, Elena Korneva, Diana G Krechikova, Aleksey L Maslyanskiy, Mikhail Samsonov, Rumen Stoilov, Elena V Zonova, Mark Genovese

Annals of the Rheumatic Diseases Apr 2022, 81 (4) 469-479; DOI: 10.1136/annrheumdis-2021-219876
Blocking GM-CSF receptor α with mavrilimumab reduces infiltrating cells, pro-inflammatory markers and neoangiogenesis in ex vivo cultured arteries from patients with giant cell arteritis
Marc Corbera-Bellalta, Roser Alba-Rovira, Sujatha Muralidharan, Georgina Espígol-Frigolé, Roberto Ríos-Garcés, Javier Marco-Hernández, Amanda Denuc, Farah Kamberovic, Patricia Pérez-Galán, Alexandra Joseph, Annalisa D’Andrea, Kent Bondensgaard, Maria C Cid, John F Paolini

Annals of the Rheumatic Diseases Apr 2022, 81 (4) 524-536; DOI: 10.1136/annrheumdis-2021-220873
Successful treatment of plasma exchange for refractory systemic juvenile idiopathic arthritis complicated with macrophage activation syndrome and severe lung disease
Satoshi Sato, Takahiro Hosokawa, Hisashi Kawashima

Annals of the Rheumatic Diseases Apr 2022, 81 (4) e61; DOI: 10.1136/annrheumdis-2020-217390
Response to: ‘Successful treatment of plasma exchange for refractory systemic juvenile idiopathic arthritis complicated with macrophage activation syndrome and severe lung disease’ by Sato et al
Vivian E Saper, Guangbo Chen, R Paul Guillerman, Purvesh Khatri, Randy Q Cron, Elizabeth D Mellins

Annals of the Rheumatic Diseases Apr 2022, 81 (4) e62; DOI: 10.1136/annrheumdis-2020-217426
Cutaneous signs and mechanisms of inflammasomopathies
Carina Borst, Dörte Symmank, Mathias Drach, Wolfgang Weninger

Annals of the Rheumatic Diseases Apr 2022, 81 (4) 454-465; DOI: 10.1136/annrheumdis-2021-220977
Interleukin-4 as an emerging therapeutic target for IgG4-related disease
Mitsuhiro Akiyama, Yuko Kaneko, Tsutomu Takeuchi

Annals of the Rheumatic Diseases Feb 2022, 81 (2) e28; DOI: 10.1136/annrheumdis-2020-216961

Main menu

Cytokines

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Cytokines

Pages